BVX-0918C / BioVaxys - LARVOL DELTA

International Patent Application Filed for Cervical Cancer Vaccine (PRNewswire) - "BioVaxys Technology Corp....announced today that it has continued to expand the patent coverage for its cancer vaccine platform by filing an international patent application through the Patent Cooperation Treaty ('PCT') for broad geographic market coverage outside the US for cervical cancer. BioVaxys has an agreement with Procare Health of Barcelona, Spain ('Procare') for clinical co-development of the Company's autologous bihaptenized cervical cancer vaccine for the EU market, in addition jointly conducting the upcoming EU Phase I clinical study of BVX-0918 in ovarian cancer."

Licensing / partnership • New P1 trial • Patent • Cervical Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor